Species |
SARS-CoV-2 |
Protein Construction |
Expressed with the mutations of G339D, S371L, S373P, S375F, K417N, N440K, G446S, S477N, T478K, E484A, Q493R, G496S, Q498R, N501Y, Y505H.
Spike RBD (Arg319-Phe541) Accession # P0DTC2 |
Poly-His |
N-term |
C-term |
|
Purity |
≥ 95% as analyzed by SDS-PAGE |
Endotoxin Level |
≤ 1 EU/μg of protein by LAL method. |
Biological Activity |
SARS-CoV-2 Spike protein RBD, Omicron Variant, His Tag can bind with human ACE2 in functional ELISA assay. |
Expression System |
Human Cells |
Theoretical Molecular Weight |
26.2 kDa |
Apparent Molecular Weight |
32-40 kDa, on SDS-PAGE under reducing conditions. |
Formulation |
Supplied as a 0.2 μm filtered solution of PBS, pH 7.4. |
Concentration |
Please refer to the COA for the specific lot. |
Storage & Stability |
Upon receiving, this product remains stable for up to 6 months at -20 °C or below. Avoid repeated freeze-thaw cycles. |
The purity is greater than 95% as determined by reducing SDS-PAGE.
Immobilized ACE-2 Fc Chimera, Human at 2 μg/ml can bind SARS-CoV-2 Spike protein RBD, Omicron Variant, His Tag (Cat.No. Z03728) with a serial dilution.
THE™ His Tag Antibody [HRP], mAb, Mouse (Cat.No. ) is used as a secondary antibody (0.2 μg/ml).
Target Background |
SARS-CoV-2 (Severe Acute Respiratory
Syndrome Coronavirus 2) also known as 2019-nCoV (2019 Novel Coronavirus) is a virus that causes illnesses ranging from the common cold to severe diseases. Recently, the new B.1.1.529 variant was confirmed in South Africa and preliminary evidence suggests an increased risk of reinfection with this variant. The B.1.1.529 variant was first reported to WHO on 24 November 2021 and WHO has designated this variant as a VOC (Variant of Concern), named Omicron. There are more than 30 mutations in the spike protein. |
Synonyms |
B.1.1.529; Omicron variant |
References |
1. .
2. . |
For laboratory research use only. Direct human use, including taking orally and injection and clinical use are forbidden.